Olmesartán Normon (Olmesartan Medoxomil)

Olmesartan medoxyl, the active ingredient in Olmesartán Normon, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and may be used in adults who need blood pressure control. GNH USA supplies Olmesartán Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxyl is used to manage conditions that involve the renin‑angiotensin system, particularly high blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Heart failure: used as part of combination therapy to improve cardiac output and symptoms.

Olmesartan medoxyl may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Cough

Serious or Rare Side Effects: - Angio‑ema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Myocardial infarction

When prescribing Olmesartan medoxyl, clinicians should consider several safety aspects.

- Renal function monitoring: assess baseline creatinine and eGFR before starting therapy. - Electrolyte balance: check serum potassium periodically, especially if combined with potassium‑sparing diuretics. - Pregnancy: avoid use during the second and third trimesters due to fetal toxicity. - Concomitant NSAID use: may reduce antihypertensive effect and increase renal risk. - Elderly patients: start at lower dose and titrate cautiously. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxyl can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes or renal impairment) - Potassium‑supplement containing products (risk of hyper‑kalemia) - Lithium (increased lithium levels and toxicity)

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (may blunt blood‑pressure reduction) - ACE inhibitors or other ARBs (combined use can cause excessive potassium rise) - Diuretics (especially thiazides, may enhance hypotensive effect).